Weining Lu, MD Hear my name

Dr. Lu is a Principal Investigator, Physician-Scientist, and Associate Professor of Medicine, Pathology, and Laboratory Medicine at Boston University and Boston Medical Center. He is also the Primary Mentor for medical students, graduate students, undergraduate students, fellows, postdocs, and junior faculty in the Nephrology Section Department of Medicine. Dr. Lu’s laboratory focuses on basic and translational research in nephrology and genetics, including kidney development, congenital anomalies of the kidney and urinary tract (CAKUT) and vesicoureteral reflux (VUR), podocyte biology and injury, pericyte biology, kidney fibrosis, ROBO/SLIT and ZEB signaling, pre-clinical animal models of kidney disease, as well as the discovery of new biomarkers, artificial-intelligence-based digital pathology tools to improve diagnosis and clinical trials and novel drug development for chronic kidney disease. His significant scientific contributions in the field of nephrology and genetics include (1) discovering ROBO2 as one of the causative genes for CAKUT and VUR (OMIM 610878), (2) identifying SLIT2/ROBO2 signaling as a novel drug target for proteinuric chronic kidney diseases, which functions as a negative regulator for podocyte adhesions in podocyte biology and injury, (3) creating the first animal model for autosomal dominant polycystic kidney disease (PKD1), and (4) discovering ZEB2 as one of the causative genes for glomerulocystic kidney disease and its essential role in kidney stromal progenitor cell differentiation and kidney fibrosis. In recognition of his seminal contribution to the development of a potential new drug for chronic kidney disease in collaboration with Pfizer, Dr. Lu was named the 2019 Boston University Innovator of the Year, an award bestowed annually on a faculty member who “translates their world-class research into inventions and innovations that benefit humankind.” This successful Academia-Industry collaboration has led to clinical trials and the first licensing agreement between Pfizer and BMC/BU. Dr. Lu is the Chair of the Core Oversight Advisory Committee in the Department of Medicine, a Co-Director of the BU Clinical and Translational Institute (CTSI) R01 Proposal Writing Workshop, the Lead Director of the Inaugural BU Biomedical Innovation Technologies Affinity Research Collaboratives (BIT-ARC) and the new B4D-ARC (Biomarkers for Diagnosis and Drug Development - A Data Science Approach), and a voting member of the Boston University Institutional Biosafety Committee (IBC). He is also a fellow of the American Society of Nephrology and the International Society of Nephrology. Dr. Lu is an Academic Editor of the scientific journal PLOS ONE and a member of the NIH grant review study sections of various grant mechanisms, including R01, R21, R03, F32, RC1, RC2, RC4, R13, R15, U01, UH2, UH3, U24, U54, P01, P20, and P50. Dr. Lu’s research program is supported by grants from the government (e.g., NIH, DOD), foundations (e.g., NKF, MOD), industry (e.g., Pfizer), and BU/BMC internal awards (e.g., DOM, Evans Center, CTSI, Ignition Award). Dr. Lu completed his training in the Renal Division and Genetics Division at Brigham and Women’s Hospital, Harvard Medical School before he was recruited to BU/BMC Nephrology Section.

RESEARCH PROGRAM:

The primary research interests of Dr. Lu’s laboratory focus on basic and translational research in four scientific areas. (1) Molecular genetics of the kidney and urinary tract development and congenital anomalies of the kidney and urinary tract (CAKUT). (2) Biological function and disease mechanism of kidney and urinary tract congenital disability genes and their roles after birth in chronic kidney diseases. (3) SLIT/ROBO and ZEB signaling in kidney and urinary tract development and disease. (4) Discovery and development of new biomarkers, novel drug targets, and therapeutics for patients with cardiovascular–kidney–metabolic (CKM) and eye diseases.

Congenital anomalies of the kidney and urinary tract (CAKUT) is a complex congenital disability with a diverse phenotypic spectrum, including kidney anomalies (e.g., renal agenesis, multicystic dysplastic kidney, hydronephrosis) and ureteric anomalies (e.g., vesicoureteral reflux, obstructive uropathy) (Ref 1, 2). CAKUT is also the leading cause of chronic kidney disease and kidney failure in children and young adults under 40 (Ref 3).

Dr. Lu’s basic and translational research program has adopted combined human and mouse molecular genetics approaches to identify developmental genes important in kidney and urinary tract development and pathogenesis of CAKUT. The first human molecular genetics approach is to study patients with CAKUT and apparent genetic defects using gene mutations, genomic imbalances, and chromosomal rearrangements as signposts to identify disease-causal genes (reverse genetics) (Ref 2). After that, molecular identification and analysis of disease genes and mutation studies in affected patients with a familial pattern of CAKUT will be carried out (forward genetics) (Ref 2, 4). The second approach is to study temporal and spatial expression patterns of disease genes in human and mouse models. Concurrently, the knockout and transgenic mouse models of human disease genes will be generated and examined to recapitulate the human disease phenotype. Once these disease genes (e.g., ROBO2, SLIT2, ZEB2) are identified and animal models are created, a multidisciplinary research approach will be taken to gain further mechanistic insights (in vivo and in vitro) on the role of these genes in normal and abnormal developmental processes of the kidney and urinary tract, and on the pathogenesis of CAKUT and kidney injury after birth (Ref 5-9). The multidisciplinary research approach includes pre-clinical animal models, patient samples, and biomarker studies, using different new biomedical technologies and research techniques in molecular genetics, developmental biology, protein biochemistry, molecular biology, pathology, pharmacology, and computing & data sciences. Dr. Lu’s basic and translational research program connects the bench and bedside. It has generated new knowledge of disease mechanisms of CAKUT and kidney disease after birth, which advances the discovery of novel drug targets and therapeutics for patients with chronic kidney disease (Ref 7-10) (https://www.eurekalert.org/pub_releases/2016-11/bumc-rip_1111516.php & https://www.eurekalert.org/pub_releases/2020-05/buso-rsn050420.php).

Current research projects in Dr. Lu’s lab include:
1). Molecular genetics of kidney and urinary tract development and congenital anomalies of the kidney and urinary tract (CAKUT).
2). Podocyte biology & injury in podocytopathy and nephrotic syndrome. Pericyte biology & injury in renal fibrosis.
3). Discover new drug targets and novel therapeutics for patients with podocytopathy, proteinuric kidney diseases, diabetic kidney disease, and cardiovascular and neovascular retinal eye diseases.
4). Develop new biomarkers and artificial intelligence-based digital pathology tools to improve the diagnosis and clinical trials of cardiovascular–kidney–metabolic (CKM) and neovascular retinal eye diseases.
Dr. Lu’s research program is supported by grants from the government (e.g., NIH, DOD), foundations (e.g., NKF, MOD), industry (e.g., Pfizer), and BU/BMC internal awards (e.g., DOM, Evans Center, CTSI, Ignition Award).

REFERENCES:
(1). Lu W, Bush KT, Nigam SK. Regulation of ureteric bud outgrowth and the consequences of disrupted development. In Kidney Development, Disease, Repair and Regeneration (ed. Little MH), Pages 209-227 (Elsevier, 2016) (http://www.sciencedirect.com/science/article/pii/B9780128001028000187)
(2). Lu W, van Eerde AM, Fan X, et al. Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux. Am J Hum Genet 2007; 80:616-632. PMID: 17357069 (http://www.ncbi.nlm.nih.gov/pubmed/17357069).
(3) Calderon-Margalit R, Golan E, Twig G, et al. History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease. N Engl J Med 2018; 378(5):4280438. PMID: 29385364 (https://www.ncbi.nlm.nih.gov/pubmed/29385364).
(4) Hwang DY, Kohl S, Fan X, et al. Mutations of the SLIT2-ROBO2 pathway genes SLIT2 and SRGAP1 Confer Risk for Congenital Anomalies of the Kidney and Urinary Tract. Hum Genet 2015; 134(8):905-916; PMID: 26026792 (http://www.ncbi.nlm.nih.gov/pubmed/26026792).
(5). Rasouly HM, Kumar S, Chen S, et al. Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic kidney disease. Kidney Int 2016; Aug 30. PMID: 27591083 (http://www.ncbi.nlm.nih.gov/pubmed/27591083).
(6) Kumar S, Fan X, Rasouly HM, et al. ZEB2 controls kidney stromal progenitor differentiation and inhibits abnormal myofibroblast expansion and kidney fibrosis. JCI Insight 2023, Jan10;(8)1:e158418. PMID: 36445780. https://insight.jci.org/articles/view/158418
(7) Fan X, Li Q, Pisarek-Horowitz A, et al. Inhibitory effects of Robo2 on nephrin: a crosstalk between positive and negative signals regulating podocyte structure. Cell Reports 2012; 2:52-61. PMID: 22840396 (http://www.ncbi.nlm.nih.gov/pubmed/22840396).
(8) Fan X, Yang H, Kumar S, et al. SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. JCI Insight 2016, Nov 17; 1(19):e86934. PMID: 27882344 (https://www.ncbi.nlm.nih.gov/pubmed/27882344).
(9) Pisarek-Horowitz A, Fan X, Kumar S, et al. Loss of Roundabout Guidance Receptor 2 (Robo2) in Podocytes Protects Adult Mice from Glomerular Injury by Maintaining Podocyte Foot Process Structure. American Journal of Pathology, 2020; 190(4):799-816. PMID: 32220420.
(https://ajp.amjpathol.org/article/S0002-9440(20)30024-9/pdf).
(10) Beck LH, Berasi SP, J. Copley B, Gorman D, Levy DI, Lim CN, Henderson JM, Salant DJ, Lu W. PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis. Kidney Int Rep 2021; 6(6):1629-1633. PMID: 34169203. DOI: https://doi.org/10.1016/j.ekir.2021.03.892

VISION STATEMENT of Dr. Lu’s laboratory on scientific research and medical education: (1) to advance new knowledge, biomedical innovation, and scientific learning; (2) to promote understanding, collaboration, diversity, and inclusion in biomedical research and education; (3) to contribute positively to the medical and biomedical innovation ecosystem and society at large.
CORE VALUES: Curiosity, Innovation, Diversity, Equity, Inclusion, Accessibility, Hard work, Perseverance, Honesty, Fair play, Courage, Integrity.

CURRENT LAB MEMBERS:

Sudhir Kumar (DVM, PhD, Ludwig Maximilians University Munich), Assistant Professor and Senior Research Scientist, 617-638-7353, kumars@bu.edu.

Xueping Fan (PhD, McGill University), Senior Research Scientist and Assistant Professor, 617-414-1772, xpfan@bu.edu.

Yash Patel (PhD, Amanbhai Patel College of Pharmacy, CHARUSAT University), Postdoctoral Research Fellow. Working on the clinical pharmacy of novel therapeutics for kidney and eye diseases in Lu Lab, ypatel3@bu.edu.

Aarushi Dabas (BS in Biology and Child Studies & Human Development, Tufts University), Research Assistant working on the Biomarker Project with the Lu and Waikar Labs, assisting with the development of the MSD immunoassay for novel biomarkers in kidney, cardiovascular, and eye diseases. adabas20@bu.edu

Alex Cooper-Hohn (BA in Economics & Pre-Medical, Brown University), Research Assistant working on the Biomarker Project with the Lu and Waikar Labs, assisting with developing the MSD immunoassay for novel biomarkers in kidney, cardiovascular, and metabolic diseases. acoope30@bu.edu

Maura Dodge (MS in Population Health Research and Epidemiology at BU School of Public Health, BS in Biology at Saint Michael’s College), PhD student at BU Chobanian & Avedisian School of Medicine, Graduate Medical Sciences (GMS), Program in Biomedical Sciences (PiBS). Maura is currently performing a rotation research project in Lu Lab titled “Evaluate the role of novel SLIT/ROBO therapeutics in developing kidneys in a pre-clinical animal model,” mcdodge@bu.edu

Ryan Chahal (Third Year [M3] Medical Student at Boston University Chobanian & Avedisian School of Medicine). Research project: “Molecular control of kidney macula densa cell development”. Current BU MD medical student, chahalry@bu.edu

Laura Dodd (Biology Major, BU College of Arts and Sciences), Currently taking the Biology undergraduate research project course in Lu Lab titled “Studying SLIT2 expression in an animal model of chronic kidney disease” (Course BI350: Junior Research in Biology, four academic credits), ldodd02@bu.edu

Aksel Laudon (Biomedical Engineering Major, Boston University College of Engineering), BS/MD student, Modular Medical/Dental Integrated Curriculum (MMEDIC) early acceptance program to BU School of Medicine MD program. Competed a BU Biomedical Engineering Senior Project in Lu Lab titled “Digital Biopsy for Glomerular Ultrastructural Measurement in Transmission EM Images” (Course: ENG BE465, two academic credits, and ENG BE466, four academic credits). Current BU Medical Student, alaudon@bu.edu

Easton Liaw (Human Physiology Major, Boston University Sargent College of Health and Rehabilitation Sciences), pre-medical student, BU Undergraduate Research Opportunities Program (UROP), Research project title: “A New Biomarker for Chronic Kidney Disease”, eliaw@bu.edu

Jiayi Amy Ji (Biochemistry & Molecular Biology Major, Boston University College of Arts and Sciences). Undergraduate Research Project in Lu Lab titled “Study the 3-D morphology of Kidney Glomerular Structure in an Animal Model of Chronic Kidney Disease”, amy2003@bu.edu

Harshita Pattam (Boston University 7-Year Combined Liberal Arts / Medical Education Program). BU Undergraduate Research Opportunities Program (UROP), Research project title: “Analyzing a Mouse Model of Congenital Anomalies of the Kidney and Urinary Tract.” Current BU BA/MD student, hpattam@bu.edu

Kaitlyn Snyder, a BU student in the combined BA/MA program [BA in Biochemistry & Molecular Biology (BMB) with an MA in Biotechnology] in the College of Arts and Sciences. BU Undergraduate Research Opportunities Program (UROP), Research project titled “Quantitative analysis of the glomerular ultrastructure in an animal model of proteinuric kidney disease using transmission electron microscopy”, kls24@bu.edu

Winston Tan, a BS/MD student currently in the 8-year Human Physiology and the Modular Medical/Dental Integrated Curriculum (MMEDIC) early acceptance program at Boston University. Working on the Inaugural BU Biomedical Innovation Technologies Affinity Research Collaboratives (BIT-ARC) research project to develop an artificial intelligence (AI) based digital pathology diagnostic tool for kidney disease, tanw@bu.edu

Omer Ege Vurkac is an undergraduate BU student majoring in Human Physiology at Boston University Sargent College. He is performing a research project in Lu Lab titled “Study Cardiorenal Syndrome in a mouse model of proteinuric chronic kidney disease.”

Kun Angel Yan (BU undergraduate student majoring in Biology, College of Arts and Sciences. She is currently a student research assistant at Lu Lab, working on pre-clinical animal models of proteinuric kidney disease. angelyk@bu.edu

Sarayu Chandiri is an undergraduate student majoring in Biology with a specialization in Cell Biology, Molecular Biology & Genetics at the Boston University College of Arts and Sciences. sarayuc@bu.edu

Simran Raikundalia (BU Presidential Scholar, Biochemistry & Molecular Biology (BMB) Major, BU College of Arts and Sciences), Currently taking the BMB undergraduate research project course in Lu Lab titled “Studying the molecular mechanisms of chronic kidney disease animal models with single-cell RNA sequencing technology” (Course BB340: Junior Research in BMB, two academic credits), simranr@bu.edu

Adhya Ramganesh (Boston University 7-Year Combined Liberal Arts / Medical Education Program). BU Undergraduate Research Opportunities Program (UROP), Research project titled “Non-invasive measurement of renal function in a pre-clinical animal model of chronic kidney disease.” Current BU BA/MD student, adhyasub@bu.edu

Sedef Yurdakul (BU Trustee Scholar, Human Physiology Major, BU Sargent College), pre-medical student, BU Undergraduate Research Opportunities Program (UROP), Research project title: “Validate a new biomarker for lupus nephritis and animal model of proteinuric kidney disease”, sedefyur@bu.edu

GRADUATED FORMER PHD STUDENTS:

Hila Milo Rasouly (PhD, Graduate Program in Genetics and Genomics, Graduate Medical Sciences, Boston University School of Medicine). PhD thesis title: “Discovery and analysis of genes important in kidney development and disease.”

Anna Pisarek-Horowitz (PhD, Graduate Program in Molecular Translational Medicine, Graduate Medical Sciences, Boston University School of Medicine). PhD thesis title: “Functional characterization of the SLIT2-ROBO2 signaling pathway in the podocyte”.

GRADUATED FORMER MS STUDENTS:

Tou S. Thao (MS in Medical Sciences Program, Graduate Medical Sciences, Boston University School of Medicine). MS thesis title: “Functional study of ROBO2 missense mutation identified in patients with congenital anomalies of the kidney and urinary tract (CAKUT)”. Medical Student at the University of Minnesota Medical School. Current PGY1 Emergency Medicine Resident Physician.

Biomedical research projects for students and postdocs are available. For inquiries regarding these research opportunities, please contact Dr. Lu at wlu@bu.edu.

Diversity, Equity, Inclusion and Accessibility

As a first-generation immigrant, Asian American, and faculty member at Boston University (BU) Chobanian & Avedisian School of Medicine (CASOM) and Boston Medical Center (BMC), I am firmly committed to diversity, equity, inclusion, and accessibility in medicine, biomedical research, education, and service.

As the principal investigator, I incorporated diversity, equity, inclusion, and accessibility in my research laboratory's vision statement and core values. We have collaborated with Pfizer in the past 12 years on basic, translational, and clinical research. We have jointly discovered and developed several novel therapeutics for chronic kidney disease, which disproportionately affects underserved, marginalized, and racial minorities, including African Americans, Hispanics, and American Indians (e.g., blacks are at 3-4 times higher risk of developing chronic kidney disease and kidney failure compared to whites).

I have served on over 30 departmental and university committees since 2006 in the Department of Medicine and Boston University Medical Campus, including the Faculty Development and Diversity Committee in the Department of Medicine and the Commitment to Operationalize Racial Equity (CORE) team in the Nephrology Section. As the current Co-Director of the BU Clinical and Translational Institute (CTSI) R-Grant Writing Workshop, the Lead Director of the Inaugural BU Biomedical Innovation Technologies Affinity Research Collaboratives (BIT-ARC), Chair of the Department of Medicine Core Oversight Advisory Committee, and the Chair of the Research Faculty Search Committee in the Nephrology Section, I commit to including racial-ethnic minorities, persons with disabilities and disadvantaged backgrounds, and women in the faculty search process, equal access to new research, education, and grant application opportunities and training.

As a BUMC Mid-Career Faculty Leadership (MFL) Program graduate, I also completed an MFL research project promoting research career success for trainees from underrepresented groups (URG) and early career faculty at the BU CASOM and BMC. At the end of the MFL Program, my team and I presented the results of this research project, titled “The NIH Diversity Supplement as a Resource to Promote BUSM Workforce Diversity,” to the leadership teams at BU and BMC to promote diversity in the BU/BMC biomedical research workforce, which led to the new BU Clinical & Translational Science Institute (CTSI) Diversity Supplement Matching Initiative.

I have served as the faculty advisor and primary mentor for many URG students at Boston University Medical Campus, including the BU CASOM Summer Undergraduate Research Program (SUPP), BUSM Summer Training as Research Scholars (STaRS) program, BUSM Biomedical Laboratory & Clinical Sciences (BLCS) Program, BU Undergraduate Research Opportunities Program (UROP), and BU Research Internship in Science and Engineering (RISE) program.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Boston Medical Center


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences





Developing Novel Therapeutics for Nephrotic Syndrome
08/01/2023 - 07/31/2027 (PI)
Department of Defense

Developing Neutralizing SLIT2/3 mAb for Treatment of Glomerular Diseases such as Focal Segmental…
02/15/2019 - 08/14/2025 (PI)
Pfizer, Inc

New Therapeutic Leads for Proteinuric Kidney Diseases
08/01/2022 - 05/31/2025 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
1R01DK133940-01

Biotherapeutic Treatment for Patients with Chronic Kidney Disease and Proteinuria
11/01/2012 - 10/31/2022 (PI)
Pfizer, Inc

Molecular Pathogenesis of Vesicoureteral Reflux
07/01/2019 - 06/30/2020 (Subcontract PI)
PI: Weining Lu, MD
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS NIH
5R01DK078226-08

Novel Biotherapeutics for the treatment of patients with chronic kidney disease and proteinuria
01/01/2014 - 12/31/2016 (PI)
Mass Life Sciences Center

Discovering Novel Urinary Tract Birth Defect Genes from Genomic Imbalances
06/01/2012 - 05/31/2016 (PI)
March of Dimes

Molecular Pathogenesis of Vesicoureteral Reflux
08/01/2008 - 02/28/2015 (PI)
NIH-NIDDK
5R01 DK078226-05

Discovering Human Birth Defect genes from chromosomal rearrangements
02/05/2009 - 01/31/2014 (PI)
Brigham & Women's NIH-NICHD

Molecular Pathogenesis of Vesicoureteral Reflux and Nephropathy
06/01/2008 - 05/31/2013 (PI)
March of Dimes

Showing 10 of 13 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs
2024 New Therapeutic Leads for Proteinuric Kidney Diseases 5R01DK133940-03
2023 New Therapeutic Leads for Proteinuric Kidney Diseases 5R01DK133940-02
2022 New Therapeutic Leads for Proteinuric Kidney Diseases 1R01DK133940-01
2018 Molecular Pathogenesis of Vesicoureteral Reflux 5R01DK078226-08 15
2017 Molecular Pathogenesis of Vesicoureteral Reflux 5R01DK078226-07 15
2016 Molecular Pathogenesis of Vesicoureteral Reflux 2R01DK078226-06A1 15
2012 Molecular Pathogenesis of Vesicoureteral Reflux 5R01DK078226-05 15
2011 Molecular Pathogenesis of Vesicoureteral Reflux 5R01DK078226-04 15
2010 Molecular Pathogenesis of Vesicoureteral Reflux 3R01DK078226-02S1 15
2010 Molecular Pathogenesis of Vesicoureteral Reflux 5R01DK078226-03 15
Showing 10 of 12 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Franceschini N, Feldman DL, Berg JS, Besse W, Chang AR, Dahl NK, Gbadegesin R, Pollak MR, Rasouly HM, Smith RJH, Winkler CA, Gharavi AG. Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group. Am J Kidney Dis. 2024 Dec; 84(6):751-766. PMID: 39033956; PMCID: PMC11585423; DOI: 10.1053/j.ajkd.2024.05.010;
     
  2. Laudon A, Zou A, Wang Z, Sharma R, Fan X, Ji J, Kim C, Qian Y, Ye Q, Chen H, Henderson JM, Zhang C, Kolachalama VB, Lu W. Digital pathology assessment of kidney glomerular filtration barrier ultrastructure in an animal model of podocytopathy. bioRxiv. 2024 Jun 17.View Related Profiles. PMID: 38948787; PMCID: PMC11212870; DOI: 10.1101/2024.06.14.599097;
     
  3. Kumar S, Fan X, Rasouly HM, Sharma R, Salant DJ, Lu W. ZEB2 controls kidney stromal progenitor differentiation and inhibits abnormal myofibroblast expansion and kidney fibrosis. JCI Insight. 2023 Jan 10; 8(1).View Related Profiles. PMID: 36445780; PMCID: PMC9870089; DOI: 10.1172/jci.insight.158418;
     
  4. Wu CW, Lim TY, Wang C, Seltzsam S, Zheng B, Schierbaum L, Schneider S, Mann N, Connaughton DM, Nakayama M, van der Ven AT, Dai R, Kolvenbach CM, Kause F, Ottlewski I, Stajic N, Soliman NA, Kari JA, El Desoky S, Fathy HM, Milosevic D, Turudic D, Al Saffar M, Awad HS, Eid LA, Ramanathan A, Senguttuvan P, Mane SM, Lee RS, Bauer SB, Lu W, Hilger AC, Tasic V, Shril S, Sanna-Cherchi S, Hildebrandt F. Copy Number Variation Analysis Facilitates Identification of Genetic Causation in Patients with Congenital Anomalies of the Kidney and Urinary Tract. Eur Urol Open Sci. 2022 Oct; 44:106-112. PMID: 36185583; PMCID: PMC9520493; DOI: 10.1016/j.euros.2022.08.004;
     
  5. David L, Martinez L, Xi Q, Fan X, Kooshesh KA, Zhang Y, Shah JV, Lu W, Maas RL, Wu H. Piezo mechanosensory channels regulate centrosome integrity. bioRxiv, Cold Spring Harbor Laboratory. 2022. View Publication
  6. Beck LH, Berasi SP, Copley JB, Gorman D, Levy DI, Lim CN, Henderson JM, Salant DJ, Lu W. PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2021 Jun; 6(6):1629-1633.View Related Profiles. PMID: 34169203; PMCID: PMC8207305; DOI: 10.1016/j.ekir.2021.03.892;
     
  7. Berasi S, Buhlmann JE, Higginson-Scott N, Shamashkin M, Russo M, Gulla SV, Juo ZS, Kodangattil SR, Lu W, Fan X, Salant DJ. RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND USES THEREOF. US Patent No. US10906955B2. Sponsor/Assignee: PFIZER and BOSTON MEDICAL CENTER. 2021. View Publication
  8. Berasi S, Buhlmann J, Shamashkin M, Russo M, Yang Y, Knowlton K, Higginson-Scott N, Lin H, Andresen C, Jones R, Fan X, Kumar S, Sharma R, Pydi A, Salant DJ, and Lu W. A ROBO2 fusion protein (PF-06730512) traps SLIT ligands and therapeutically ameliorates podocyte injury. 2020 Kidney Week. 2020. View Publication
  9. Vargas SR, Ritenour C, Tyszkiewicz C, Hwang SK, Liu CN, Tomlinson L, Berasi S, Fan X, Lu W, Yang H. Deep Learning for Quantitative Image Analysis of Morphological Changes in Podocyte Foot Processes in Electron Micrographs of Rat Model of Passive Heymann Nephritis. 2020 Digital Pathology & AI Congress. 2020. View Publication
  10. Connaughton DM, Dai R, Owen DJ, Marquez J, Mann N, Graham-Paquin AL, Nakayama M, Coyaud E, Laurent EMN, St-Germain JR, Blok LS, Vino A, Klämbt V, Deutsch K, Wu CW, Kolvenbach CM, Kause F, Ottlewski I, Schneider R, Kitzler TM, Majmundar AJ, Buerger F, Onuchic-Whitford AC, Youying M, Kolb A, Salmanullah D, Chen E, van der Ven AT, Rao J, Ityel H, Seltzsam S, Rieke JM, Chen J, Vivante A, Hwang DY, Kohl S, Dworschak GC, Hermle T, Alders M, Bartolomaeus T, Bauer SB, Baum MA, Brilstra EH, Challman TD, Zyskind J, Costin CE, Dipple KM, Duijkers FA, Ferguson M, Fitzpatrick DR, Fick R, Glass IA, Hulick PJ, Kline AD, Krey I, Kumar S, Lu W, Marco EJ, Wentzensen IM, Mefford HC, Platzer K, Povolotskaya IS, Savatt JM, Shcherbakova NV, Senguttuvan P, Squire AE, Stein DR, Thiffault I, Voinova VY, Somers MJG, Ferguson MA, Traum AZ, Daouk GH, Daga A, Rodig NM, Terhal PA, van Binsbergen E, Eid LA, Tasic V, Rasouly HM, Lim TY, Ahram DF, Gharavi AG, Reutter HM, Rehm HL, MacArthur DG, Lek M, Laricchia KM, Lifton RP, Xu H, Mane SM, Sanna-Cherchi S, Sharrocks AD, Raught B, Fisher SE, Bouchard M, Khokha MK, Shril S, Hildebrandt F. Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations. Am J Hum Genet. 2020 10 01; 107(4):727-742. PMID: 32891193; PMCID: PMC7536580; DOI: 10.1016/j.ajhg.2020.08.013;
     
Showing 10 of 85 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 85 publications over 24 distinct years, with a maximum of 14 publications in 2019

YearPublications
19972
19991
20002
20012
20024
20032
20051
20061
20073
20081
20113
20121
20133
20146
20158
20167
20176
20187
201914
20204
20212
20222
20231
20242

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

2023 Boston University: Ignition Awards
2023 Department of Defense (DOD): Department of Defense PRMRP Technology/Therapeutic Development Award
2023 International Society of Nephrology: Fellow of the International Society of Nephrology (FISN)
2019 Boston University: Innovator of the Year
2018 American Society of Nephrology (ASN): Fellow of the American Society of Nephrology (FASN)
2014 Massachusetts Life Sciences Center (MLSC): Massachusetts Life Sciences Center Cooperative Research Matching Grant Award
2012 Pfizer: Pfizer Centers for Therapeutic Innovation Drug Discovery and Development Project Grant Awards
2008-2016 March of Dimes Foundation: Birth Defect Research Grant Awards
2008 National Institutes of Health (NIH): NIH Research Project R01 Grant Award (DK078226: funded with 3 percentile review score)
2007-2008 The National Kidney Foundation (NKF) of MA/RI/NH/VT, USA: Pediatric Renal Research Award
2005-2007 National Kidney Foundation, USA: Young Investigator Grant Award
2005 Chinese American Society of Nephrology (CASN), USA: Young Investigator Award
1998 Brigham and Women's Hospital, Harvard Medical School: Travel Award
1997 NIH-NIDDK Polycystic Kidney Disease Workshop, USA: Young Investigator Travel Award
1996 American Society of Nephrology (ASN): Travel Award
1989 Zhejiang University School of Medicine: Excellent Medical Intern Award
1988 Zhejiang University School of Medicine: Excellent Medical Student Award

Dr. Lu has completed the Boston University Medical Center CTSI Mentor Training Program.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Lu's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department